特泽鲁单抗
 | 此条目可参照英语维基百科相应条目来扩充。 (2025年1月14日) |
 特泽鲁单抗抑制 TSLP 信号传导的结构基础 (PDB 5J13)[1] | |
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | 胸腺基质淋巴细胞生成素 (TSLP) |
| 临床资料 | |
| 商品名 | Tezspire |
| 其他名称 | MEDI9929, AMG 157, tezepelumab-ekko |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622010 |
| 核准状况 | |
| 给药途径 | 皮下注射 |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 |
|
| 识别信息 | |
| CAS号 | 1572943-04-4 |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6400H9844N1732O1992S52 |
| 摩尔质量 | 144,590.40 g·mol−1 |
特泽鲁单抗（INN：tezepelumab）用于治疗哮喘[9] [10]。特别适用其他药物无法控制的严重哮喘，患者需12岁以上[10]。每4周皮下注射一次[10]。
最常见的副作用包括关节痛和喉咙痛[10]。其他副作用包括可能有过敏反应[9]。虽然无证据显示孕期使用对胎儿有害，但研究仍不充分[9]。它是一种单克隆抗体，可阻断胸腺基质淋巴细胞生成素（TSLP），并减少呼吸道的发炎反应[9] [10]。
特泽鲁单抗于2021年及2022年在美国及欧洲取得医疗使用许可[9] [10]。虽然已在英国取得许可，但截至2022年整尚未上市[11]
参考文献
[编辑]- ^ Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma. Nature Communications. April 2017, 8 (1): 14937. Bibcode:2017NatCo...814937V. PMC 5382266
. PMID 28368013. doi:10.1038/ncomms14937.
- ^ Tezspire Product information. Health Canada. 25 April 2012 [1 October 2022]. （原始内容存档于1 October 2022）.
- ^ Summary Basis of Decision - Tezspire. Health Canada. 23 October 2014 [24 January 2023]. （原始内容存档于24 January 2023）.
- ^ Details for: Tezspire. Health Canada. 19 October 2022 [3 March 2024].
- ^ Tezspire- tezepelumab-ekko injection, solution. DailyMed. [24 December 2021]. （原始内容存档于25 December 2021）.
- ^ Tezspire (tezepelumab) approved in the US for severe asthma. AstraZeneca (新闻稿). 17 December 2021 [17 December 2021]. （原始内容存档于18 December 2021）.
- ^ Tezspire EPAR. European Medicines Agency. 19 July 2022 [21 September 2022]. （原始内容存档于22 September 2022）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Tezspire Product information. Union Register of medicinal products. 12 December 2022 [3 March 2023]. （原始内容存档于27 October 2022）.
- ^ 9.0 9.1 9.2 9.3 9.4 Tezspire- tezepelumab-ekko injection, solution. DailyMed. [24 December 2021]. （原始内容存档于25 December 2021）.
- ^ 10.0 10.1 10.2 10.3 10.4 10.5 Tezspire EPAR. European Medicines Agency. 19 July 2022 [21 September 2022]. （原始内容存档于22 September 2022）.
- ^ Tezepelumab. SPS - Specialist Pharmacy Service. 16 March 2018 [24 October 2022]. （原始内容存档于6 March 2022）.
外部链接
[编辑]- Clinical trial number NCT02054130 for "Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma" at ClinicalTrials.gov
- Clinical trial number NCT03347279 for "Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)" at ClinicalTrials.gov
